1. Home
  2. BEAM vs RDW Comparison

BEAM vs RDW Comparison

Compare BEAM & RDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$26.87

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

Logo Redwire Corporation

RDW

Redwire Corporation

N/A

Current Price

$8.36

Market Cap

2.3B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAM
RDW
Founded
2017
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Military/Government/Technical
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.3B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
BEAM
RDW
Price
$26.87
$8.36
Analyst Decision
Strong Buy
Buy
Analyst Count
15
11
Target Price
★ $49.38
$14.28
AVG Volume (30 Days)
1.8M
★ 9.9M
Earning Date
11-10-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 82.31
2.98
EPS
N/A
★ N/A
Revenue
$24,000.00
★ $335,381,000.00
Revenue This Year
N/A
$41.71
Revenue Next Year
$14.48
$18.75
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 33.33
10.29
52 Week Low
$20.23
$4.87
52 Week High
$38.26
$26.64

Technical Indicators

Market Signals
Indicator
BEAM
RDW
Relative Strength Index (RSI) 55.77 38.04
Support Level $25.29 $7.72
Resistance Level $28.87 $10.43
Average True Range (ATR) 1.47 0.52
MACD 0.47 0.07
Stochastic Oscillator 55.38 32.82

Price Performance

Historical Comparison
BEAM
RDW

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About RDW Redwire Corporation

Redwire Corp is an integrated space and defense technology company focused on technologies including aerospace infrastructure, autonomous systems and multi-domain operations, leveraging digital engineering and artificial intelligence automation. The Company develops and provides mission critical solutions based on space and defense technology platform offerings for government, commercial and civil customers through both short- and long-duration projects. These include technologies and production capability for next-generation spacecraft, large space infrastructure, microgravity capabilities, combat autonomous systems, optical sensors and radio frequency payloads that provide intelligence, surveillance, and reconnaissance capabilities for U.S. and allied nations across multiple domains.

Share on Social Networks: